Reviewing iBio Inc. (IBIO)’s and Constellation Pharmaceuticals Inc. (NASDAQ:CNST)’s results

iBio Inc. (NYSEAMERICAN:IBIO) and Constellation Pharmaceuticals Inc. (NASDAQ:CNST), both competing one another are Biotechnology companies. We will contrast their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iBio Inc. N/A 46.71 16.94M -1.39 0.00
Constellation Pharmaceuticals Inc. N/A 0.00 56.96M -2.14 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of iBio Inc. and Constellation Pharmaceuticals Inc.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
iBio Inc. 0.00% -164.6% -44.6%
Constellation Pharmaceuticals Inc. 0.00% 0% 0%

Insider and Institutional Ownership

Roughly 6.7% of iBio Inc. shares are owned by institutional investors while 64.8% of Constellation Pharmaceuticals Inc. are owned by institutional investors. Insiders owned 45.3% of iBio Inc. shares. Insiders Competitively, owned 42.9% of Constellation Pharmaceuticals Inc. shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
iBio Inc. -7.69% -8.86% -13.25% -45.86% -52% -59.35%
Constellation Pharmaceuticals Inc. -1.69% -3.33% -26.49% 0% 0% -49.57%

For the past year iBio Inc.’s stock price has bigger decline than Constellation Pharmaceuticals Inc.


Constellation Pharmaceuticals Inc. beats iBio Inc. on 4 of the 7 factors.

iBio, Inc., a biotechnology company, focuses on developing and commercializing pharmaceutical product applications using its platform in the United States and internationally. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has license and collaboration agreements with Caliber Biotherapeutics LLC and Fiocruz; and collaboration agreements with the A & M University System, AzarGen Biotechnologies (Pty) Ltd, Fraunhofer Center for Molecular Biotechnology, and Theoremdx, Inc. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is based in New York, New York.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.